131 related articles for article (PubMed ID: 31070763)
1. Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer.
Yoo HJ; Lim MC; Seo SS; Kang S; Joo J; Park SY
Jpn J Clin Oncol; 2019 Sep; 49(9):832-838. PubMed ID: 31070763
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
Alvarez Secord A; Jones EL; Hahn CA; Petros WP; Yu D; Havrilesky LJ; Soper JT; Berchuck A; Spasojevic I; Clarke-Pearson DL; Prosnitz LR; Dewhirst MW
Int J Hyperthermia; 2005 Jun; 21(4):333-47. PubMed ID: 16019859
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth.
Yang W; Han GH; Shin HY; Lee EJ; Cho H; Chay DB; Kim JH
Int J Hyperthermia; 2019; 36(1):9-20. PubMed ID: 30428738
[TBL] [Abstract][Full Text] [Related]
4. Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients.
Fiorentini G; Sarti D; Casadei V; Milandri C; Dentico P; Mambrini A; Nani R; Fiorentini C; Guadagni S
Integr Cancer Ther; 2019; 18():1534735419878505. PubMed ID: 31561722
[No Abstract] [Full Text] [Related]
5. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis.
Roussakow SV
BMJ Open; 2017 Nov; 7(11):e017387. PubMed ID: 29102988
[TBL] [Abstract][Full Text] [Related]
6. Relationship between Energy Dosage and Apoptotic Cell Death by Modulated Electro-Hyperthermia.
Kao PH; Chen CH; Tsang YW; Lin CS; Chiang HC; Huang CC; Chi MS; Yang KL; Li WT; Kao SJ; Minnaar CA; Chi KH; Wang YS
Sci Rep; 2020 Jun; 10(1):8936. PubMed ID: 32488092
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area.
van Meerten E; Franckena M; Wiemer E; van Doorn L; Kraan J; Westermann A; Sleijfer S
Oncologist; 2015 Mar; 20(3):241-2. PubMed ID: 25660155
[TBL] [Abstract][Full Text] [Related]
8. Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.
Jones E; Alvarez Secord A; Prosnitz LR; Samulski TV; Oleson JR; Berchuck A; Clarke-Pearson D; Soper J; Dewhirst MW; Vujaskovic Z
Int J Hyperthermia; 2006 Mar; 22(2):161-72. PubMed ID: 16754599
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the effects of mEHT on the treatment-related toxicity and quality of life of HIV-positive cervical cancer patients.
Minnaar CA; Kotzen JA; Naidoo T; Tunmer M; Sharma V; Vangu MD; Baeyens A
Int J Hyperthermia; 2020; 37(1):263-272. PubMed ID: 32180481
[No Abstract] [Full Text] [Related]
10. Hyperthermia combined with chemotherapy
Fiorentini G; Sarti D; Mambrini A; Hammarberg Ferri I; Bonucci M; Sciacca PG; Ballerini M; Bonanno S; Milandri C; Nani R; Guadagni S; Dentico P; Fiorentini C
World J Clin Oncol; 2023 Jun; 14(6):215-226. PubMed ID: 37398545
[TBL] [Abstract][Full Text] [Related]
11. Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial.
Kim K; Kim JH; Kim SC; Kim YB; Nam BH; No JH; Cho H; Ju W; Suh DH; Kim YH
Exp Ther Med; 2021 Jul; 22(1):787. PubMed ID: 34055086
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
13. Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin.
Hahn CA; Jones EL; Blivin JL; Sanders LL; Yu D; Dewhirst MW; Secord AA; Prosnitz LR
Int J Hyperthermia; 2005 Jun; 21(4):349-57. PubMed ID: 16019860
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
Baekelandt M; Lehne G; Tropé CG; Szántó I; Pfeiffer P; Gustavssson B; Kristensen GB
J Clin Oncol; 2001 Jun; 19(12):2983-93. PubMed ID: 11408493
[TBL] [Abstract][Full Text] [Related]
16. Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients.
Fiorentini G; Sarti D; Ranieri G; Gadaleta CD; Fiorentini C; Milandri C; Mambrini A; Guadagni S
World J Clin Oncol; 2021 Nov; 12(11):1064-1071. PubMed ID: 34909400
[TBL] [Abstract][Full Text] [Related]
17. The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer.
Ou J; Zhu X; Lu Y; Zhao C; Zhang H; Wang X; Gui X; Wang J; Zhang X; Zhang T; Pang CLK
Eur J Pharm Sci; 2017 Nov; 109():412-418. PubMed ID: 28847527
[TBL] [Abstract][Full Text] [Related]
18. In vitro comparison of conventional hyperthermia and modulated electro-hyperthermia.
Yang KL; Huang CC; Chi MS; Chiang HC; Wang YS; Hsia CC; Andocs G; Wang HE; Chi KH
Oncotarget; 2016 Dec; 7(51):84082-84092. PubMed ID: 27556507
[TBL] [Abstract][Full Text] [Related]
19. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
